Immunology

TScan Strengthens Board of Directors with Appointment of Douglas Fambrough, Ph.D.

Retrieved on: 
Tuesday, March 10, 2020
Oncology, Health, Medical devices, Genetics, Other Health, Pharmaceutical, Biotechnology, Medical specialties, Branches of biology, Immune system, Medicine, Immunology, Cell signaling, T-cell receptor, V(D)J recombination, Antigen

TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR) therapies which reprogram a patients own T cells to recognize shared cancer targets, today announced the appointment of Douglas Fambrough, Ph.D., to its board of directors (BoD).

Key Points: 
  • TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR) therapies which reprogram a patients own T cells to recognize shared cancer targets, today announced the appointment of Douglas Fambrough, Ph.D., to its board of directors (BoD).
  • Dougs work as a genomic scientist and the founder and leader of Dicerna make him a perfect fit on our board of directors, said David P. Southwell, President and Chief Executive Officer, TScan.
  • Im delighted to be working with David and the TScan board as they build out a pipeline based on their novel discovery platform, commented Dr. Fambrough.
  • The TScan technology platform utilizes a genome-wide, high-throughput, and unbiased screening process to discover novel antigens and novel TCRs to target them.

2020 Allergy Capitals™ Report Ranks the Most Challenging Cities in the U.S. for Allergies

Retrieved on: 
Tuesday, March 10, 2020
Medical specialties, Immunology, Medicine, Allergology, Immune system, Food allergies, RTT, Asthma and Allergy Foundation of America, Allergy, Asthma and Allergy Friendly

The Allergy Capitals report helps raise awareness about the impact of seasonal allergies, how people can prepare and start proper treatment.

Key Points: 
  • The Allergy Capitals report helps raise awareness about the impact of seasonal allergies, how people can prepare and start proper treatment.
  • Local communities can also use the report as a tool to identify how to better meet the needs of their residents living with allergies and allergic asthma.
  • The Allergy Capitals ranking is an annual research and educational project of AAFA, designed to help patients recognize, prevent and safely treat allergy symptoms.
  • AAFA also helps consumers identify healthier products for the home and indoor environment through the asthma & allergy friendly Certification Program.

Berkeley Lights Launches Cell Line Development 2.0 Workflow to Find Top Clones for Complex Antibody Therapeutics

Retrieved on: 
Monday, March 9, 2020
Branches of biology, Immunology, Biology, Medicine, Antibody, Clone

The new Opto CLD 2.0 workflow enables measurements of antibody production across thousands of clones using Berkeley Lights' SpotLight assays.

Key Points: 
  • The new Opto CLD 2.0 workflow enables measurements of antibody production across thousands of clones using Berkeley Lights' SpotLight assays.
  • It targets different regions of antibody molecules, extending the range of complex antibody molecules for which top clones can be selected.
  • "By developing new assays that target different regions of antibody molecules, Berkeley Lights Opto CLD 2.0 workflow empowers the selection of top clones secreting both traditional and non-traditional antibody molecules."
  • Berkeley Lights has the complete solution to find the best cells by functionally screening and recovering individual cells for antibody discovery, cell line development, T cell analysis, and synthetic biology.

Berkeley Lights Launches Cell Line Development 2.0 Workflow to Find Top Clones for Complex Antibody Therapeutics

Retrieved on: 
Monday, March 9, 2020
Immunology, Branches of biology, Antibody, Glycoproteins, Biology, Health, Workflow, Immune system

The Opto Cell Line Development 2.0 workflow, designed for the Beaconoptofluidic instrument, generates in just days the best production cell lines for complex antibody therapeutics with more than 99% monoclonality assurance

Key Points: 
  • The Opto Cell Line Development 2.0 workflow, designed for the Beaconoptofluidic instrument, generates in just days the best production cell lines for complex antibody therapeutics with more than 99% monoclonality assurance
    EMERYVILLE, California, March 9, 2020 /PRNewswire/ --Today, Berkeley Lights, a leader in cell selection, launched a new workflow for the Beacon instrument: the Opto Cell Line Development 2.0 (Opto CLD 2.0).
  • The new Opto CLD 2.0 workflow enables measurements of antibody production across thousands of clones using Berkeley Lights' SpotLight assays.
  • It targets different regions of antibody molecules, extending the range of complex antibody molecules for which top clones can be selected.
  • "By developing new assays that target different regions of antibody molecules, Berkeley Lights Opto CLD 2.0 workflow empowers the selection of top clones secreting both traditional and non-traditional antibody molecules."

TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting

Retrieved on: 
Monday, March 9, 2020
Life sciences, Medical specialties, Health, Pharmaceutical industry, Autoimmunity, Immunology, Sjögren syndrome, Biopharmaceutical

Abstracts are now available online and can be accessed via the below links or on the AAN meeting website at www.aan.com .

Key Points: 
  • Abstracts are now available online and can be accessed via the below links or on the AAN meeting website at www.aan.com .
  • Following each presentation, the data presented will be available on the Publications page of the Companys website at www.tgtherapeutics.com.
  • TG Therapeuticsis a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Berkeley Lights Launches T Cell Receptor Sequencing Kit to Increase Efficiency of T Cell Receptor Discovery

Retrieved on: 
Thursday, March 5, 2020
Medical specialties, Branches of biology, Immunology, Medicine, Immune system, T cell, Antibody, T-cell receptor, Cytotoxic T cell

EMERYVILLE, Calif., March 5, 2020 /PRNewswire/ -- Today, Berkeley Lights, a leader in cell selection, launched their new T Cell Receptor Sequencing Kit (TCRseq Kit).

Key Points: 
  • EMERYVILLE, Calif., March 5, 2020 /PRNewswire/ -- Today, Berkeley Lights, a leader in cell selection, launched their new T Cell Receptor Sequencing Kit (TCRseq Kit).
  • The TCRseq Kit enables users of Berkeley Lights' Beacon and Lightning instruments to recover functionally validated T cell receptors (TCRs) from a cell sample that has as few as 10,000 input cells.
  • The TCRseq Kit enables Berkeley Lights platform users to first characterize the T cell function using the Berkeley Lights Cell Therapy Development Suite and then only sequence the T cells that matter.
  • Berkeley Lights has the complete solution to find the best cells by functionally screening and recovering individual cells for antibody discovery, cell line development, T cell analysis, and synthetic biology.

Berkeley Lights Launches T Cell Receptor Sequencing Kit to Increase Efficiency of T Cell Receptor Discovery

Retrieved on: 
Thursday, March 5, 2020
Branches of biology, Medical specialties, Cell biology, Immunology, Immune system, CD117, T cell, T-cell receptor

The T Cell Receptor Sequencing Kit (TCRseq Kit) allows users of Berkeley Lights platforms to more efficiently identify, recover, and sequence T cells of interest

Key Points: 
  • The T Cell Receptor Sequencing Kit (TCRseq Kit) allows users of Berkeley Lights platforms to more efficiently identify, recover, and sequence T cells of interest
    EMERYVILLE, Calif., March 5, 2020 /PRNewswire/ -- Today, Berkeley Lights, a leader in cell selection, launched their new T Cell Receptor Sequencing Kit (TCRseq Kit).
  • The TCRseq Kit enables users of Berkeley Lights' Beacon and Lightning instruments to recover functionally validated T cell receptors (TCRs) from a cell sample that has as few as 10,000 input cells.
  • The TCRseq Kit enables Berkeley Lights platform users to first characterize the T cell function using the Berkeley Lights Cell Therapy Development Suite and then only sequence the T cells that matter.
  • Berkeley Lights' Beacon and Lightning instruments and the TCRseq Kit are: For Research Use Only.

Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020

Retrieved on: 
Thursday, March 5, 2020
Biotechnology, Immune system, Immunology, Monoclonal antibody, GD2, Life sciences, Biology, Branches of biology

Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.

Key Points: 
  • Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.
  • The Company has a broad and advanced product pipeline, including two pivotal-stage product candidatesnaxitamab and omburtamabwhich target tumors that express GD2 and B7-H3, respectively.
  • Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
  • Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges.

Neoleukin Therapeutics to Host 2019 Financial Results Conference Call and Webcast on March 12, 2020

Retrieved on: 
Thursday, March 5, 2020
Health, Medicine, Branches of biology, Immunology, Pharmaceutical industry, Pharmacy, Medicinal chemistry, Autoimmunity, Biopharmaceutical, Medication, Agonist, Immunotherapy

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity usingde novoprotein design technology.

Key Points: 
  • Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity usingde novoprotein design technology.
  • Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.
  • Neoleukins lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
  • These statements are subject to numerous risks and uncertainties, including market conditions, that could cause actual results to differ materially from what Neoleukin expects.

World Premiere: Diaccurate, The Biotech Created by Truffle Capital, Reveals the Mechanism of Immune Disablement in HIV Infection

Retrieved on: 
Wednesday, March 4, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious diseases, Clinical trials, Medical specialties, Medicine, Branches of biology, Immunology, Glycoproteins, HIV/AIDS, Pandemics, HIV, CD4, Idiopathic CD4+ lymphocytopenia, Division of Acquired Immunodeficiency Syndrome, Diaccurate, Truffle Capital

This major breakthrough opens novel therapeutic avenues to restore CD4+ T-cell function and boost the immune system of HIV-infected patients.

Key Points: 
  • This major breakthrough opens novel therapeutic avenues to restore CD4+ T-cell function and boost the immune system of HIV-infected patients.
  • AIDS (Acquired Immunodeficiency Syndrome) is a disease of the immune system caused by the Human Immunodeficiency Virus (HIV).
  • The mission of Truffle Capital is to help the creation and development of young innovating companies, capable of becoming tomorrows leaders.
  • In 2019, Truffle Capital announced having raised almost 400 million in new institutional funds, including 250 million for new BioMedTech investments.